Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Substantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in...

Related Keywords

Israel ,London ,City Of ,United Kingdom ,Germany ,Spain ,Italy ,Belgium ,Brussels ,Bruxelles Capitale ,United States ,France ,Ozlem Goker Alpan ,Pamela Foulds ,Naomi Aoki ,Treatment Center ,Exchange Commission ,Nasdaq ,Company Annual Report On Form ,European Society Of Gene Cell Therapy ,Freeline Therapeutics Holdings ,Globenewswire Inc ,Linkedin ,Rare Disorder Research ,Therapeutics Holdings ,Cell Therapy ,Chief Medical ,New Clinical Data ,First In Human Clinical Trial ,Gaucher Disease Type ,Annual Report ,Statement Regarding Forward Looking ,Investor Contact ,Vice President ,Investor Relations ,Markets ,